Trial Profile
A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use or Receiving Opioid Substitution Therapy
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms DARLO-C
- 21 May 2019 Status changed from active, no longer recruiting to discontinued.
- 26 Feb 2019 Planned End Date changed from 1 Feb 2019 to 1 Aug 2019.
- 26 Feb 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Feb 2019.